Literature DB >> 30531326

Immunoreactivity for Sox10 in Basaloid Neoplasms of The Skin.

James W Bush1, Alejandro A Gru, Mark R Wick.   

Abstract

Basaloid tumors of the skin pose a diagnostic challenge to pathologists, because the differential diagnosis is broad, sometimes with subtle differentiating features. We evaluated SOX10 expression in 120 primary cutaneous tumors with epidermal, sweat glandular, neuroendocrine/neuroectodermal, follicular, and sebaceous lineages. Our findings were compared with those of previous studies that evaluated SOX10 in tumors of the skin. SOX10 staining was seen in the majority of sweat gland tumors with the exception of syringoma and microcystic adnexal carcinoma. There were no immunoreactive cases among epidermal, neuroendocrine/neuroectodermal, follicular, or sebaceous tumors. These findings are comparable to reported in previous studies, and show SOX10 can be a useful adjunct in the differential diagnosis of nodular basaloid skin tumors. That marker has less utility in the assessment of sclerosing basaloid cutaneous neoplasms, because such tumors are almost uniformly nonreactive for it.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30531326     DOI: 10.1097/PAI.0000000000000721

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  2 in total

Review 1.  Sex-Determining Region Y Chromosome-Related High-Mobility-Group Box 10 in Cancer: A Potential Therapeutic Target.

Authors:  Liming Yu; Fan Peng; Xue Dong; Ying Chen; Dongdong Sun; Shuai Jiang; Chao Deng
Journal:  Front Cell Dev Biol       Date:  2020-12-03

Review 2.  Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors.

Authors:  Nicolas Macagno; Pierre Sohier; Thibault Kervarrec; Daniel Pissaloux; Marie-Laure Jullie; Bernard Cribier; Maxime Battistella
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.